Cost savings with a new screening algorithm for pulmonary arterial hypertension in systemic sclerosis

Internal Medicine Journal

Volumn 45, Issue 11, 2015, Pages 1134-1140

  Quinlivan, A ^a,b   Thakkar, V ^a,d,e   Stevens, W ^a   Morrisroe, K ^a   Prior, D ^a,b   Rabusa, C ^a   Youssef, P ^f   Gabbay, E ^g   Roddy, J ^h   Walker, J G ⁱ   Zochling, J ^m   Sahhar, J ^c   Nash, P ⁿ   Lester, S ^l   Rischmueller, M ^k,l   Proudman, S M ^j,k   Nikpour, M ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d LIVERPOOL HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF NOTRE DAME   (Australia)

^h ROYAL PERTH HOSPITAL   (Australia)

ⁱ FLINDERS MEDICAL CENTRE   (Australia)

^j ROYAL ADELAIDE HOSPITAL   (Australia)

^k UNIVERSITY OF ADELAIDE   (Australia)

^l QUEEN ELIZABETH HOSPITAL   (Australia)

^m UNIVERSITY OF TASMANIA   (Australia)

ⁿ UNIVERSITY OF QUEENSLAND   (Australia)

more..

Author keywords

Algorithm; Cost; Pulmonary arterial hypertension; Scleroderma; Screening

Indexed keywords

ADULT; ALGORITHM; ARTICLE; AUSTRALIAN; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST CONTROL; FEMALE; HEALTH CARE COST; HEART CATHETERIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCREENING; SCREENING TEST; SYSTEMIC SCLEROSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; AGED; CLINICAL TRIAL; ECHOCARDIOGRAPHY; ECONOMICS; HYPERTENSION, PULMONARY; LUNG FUNCTION TEST; MASS SCREENING; MULTICENTER STUDY; PROCEDURES; PROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC;

AGED; ALGORITHMS; COHORT STUDIES; COST SAVINGS; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MASS SCREENING; MIDDLE AGED; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 84946916898     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12890     Document Type: Article

References (25)

1. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J 2007; 37: 485-494.
2. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE etal. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-944.
4. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
5. Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ etal. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S78-84.
6. Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A etal. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology 2010; 49: 490-500.
7. Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer GMB etal. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. The Lancet 2008; 371: 2093-2100.
8. Denton CP, Hachulla E. Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening. Eur Respir Rev 2011; 20: 270-276.
9. Humbert M, Gerry Coghlan J, Khanna D. Early detection and management of pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 306-312.
10. Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ etal. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20-25.
11. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D etal. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-3530.
12. Humbert M, Sitbon O, Yaïci A, Montani D, O'Callaghan DS, Jaïs X etal. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J 2010; 36: 549-555.
13. Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J etal. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 682-691.
14. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR etal. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
15. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM etal. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004; 43: 461-466.
16. Members ATF, Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery J-L etal. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
17. Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE etal. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med 2009; 179: 615-621.
18. Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D etal. N-terminal probrain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 2012; 14: R143.
19. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E etal. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-291.
20. Williams MH, Handler CE, Akram R, Smith CJ, Das C, Smee J etal. Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-1494.
21. Thakkar V, Stevens W, Prior D, Byron J, Patterson K, Hissaria P etal. S.4.1 N-terminal pro-brain natriuretic peptide levels predict incident pulmonary arterial hypertension in SSc. Rheumatology 2012; 51: ii8-10.
22. Vachiéry J-L, Coghlan G. Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 2009; 18: 162-169.
23. Proudman S, Byron J, Zochling J, Youssef P, Nash P, Tymms K etal. An on-line screening tool for cardiopulmonary complications of scleroderma-the Australian Scleroderma Screening Program. Arthritis Rheum 2009; 60: S641.
24. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A etal. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-2747.
25. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W etal. Development of a novel, N-Terminal-proBNP (NTproBNP) assay with a low detection limit. Scandinavian J Clin Lab Invest 1999; 59: 177-181.